NCT04542291

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.

Conditions

• Pancreas Cancer
• Pancreatic Cancer
• Cancer of the Pancreas

Interventions

Type	Name	Description
DRUG	Dapagliflozin	Dapagliflozin will be provided for this trial
DEVICE	BIOSENSE meters	-Being used in this trial to evaluate utility for assessing breath ketones

Timeline

• Start date: 2021-02-25
• Primary completion: 2021-12-24
• Completion: 2022-01-19
• First posted: 2020-09-09
• Last updated: 2023-02-14
• Results posted: 2023-01-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study